Abstract: To improve the diagnosis and treatment of soft tissue sarcoma in China， to carry out the multidisciplinary collaboration in our country better， to form and develop the consensus in accordance with China’s national conditions， we work out this clinical pathway under the leader of Sarcoma Group of CSCO（Chinese Society Of Clinical Oncology） and Sarcoma Group of CACA（Chinese Anti-Cancer Association）. The clinical pathway is based on evidence-based medicine evidence with wide literature review and national experience in China. This article mainly focuses on the interpretation and understanding of various aspects related to this clinical pathway.